Highly purified CD34-positive cells reconstitute hematopoiesisC I Civin
Oncology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Clin Oncol 14:2224-33. 1996
..In particular, we wanted to determine if the CD34+ marrow cell grafts generated hematopoietic reconstitution, since a positive result would motivate further development and use of this methodology...
- Steel factor supports the cycling of isolated human CD34+ cells in the absence of other growth factors
S D Gore
Johns Hopkins Oncology Center, Baltimore, MD 21287 8963, USA
Exp Hematol 23:413-21. 1995
..Thus, while the effects of SF are most marked in combination with other growth factors, SF appears to bind to and directly maintain the active cell-cycle characteristics of isolated CD34+ cells...
- High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector
Z Gao
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
Stem Cells 19:247-59. 2001
..This study provides evidence that lentiviral vectors transduced both short-term and long-term engrafting human cells, and mediated persistent transgene expression at high levels in multiple lineages of hematopoietic cells...
- The adapter protein CrkL associates with CD34
D M Felschow
Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Bunting Blaustein Cancer Research Building, 1650 Orleans St, Baltimore, MD, USA
Blood 97:3768-75. 2001
..Our investigations shed new light on signaling pathways of CD34 by demonstrating that CD34 couples to the hematopoietic adapter protein CrkL. (Blood. 2001;97:3768-3775)..
- JAK3: expression and mapping to chromosome 19p12-13.1
M G Safford
Oncology Center, Department of Biology, Johns Hopkins University, Baltimore, Maryland 21287, USA
Exp Hematol 25:374-86. 1997
..Using fluorescence in situ hybridization we have localized JAK3 to 19p12-13.1, the same region of chromosome 19 to which the LEY I-L hormone maps (19p12-13.2)...
- SZF1: a novel KRAB-zinc finger gene expressed in CD34+ stem/progenitor cells
C Liu
The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 5001, USA
Exp Hematol 27:313-25. 1999
..The expression pattern of SZF1 transcripts and the transcriptional repression of a CD34+-specific promoter demonstrate a possible role for SZF1 in hematopoietic stem/progenitor cell differentiation...
- CBFbeta-SMMHC slows proliferation of primary murine and human myeloid progenitors
S Chaudhuri
Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
Leukemia 19:921-9. 2005
..These findings support the development of therapeutics that target the ability of CBFbeta-SMMHC to interact with AML1 or to multimerize via its assembly competence domain...
- Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34- cell preparations
Z Gao
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Exp Hematol 29:910-21. 2001
..Hematopoiesis derived from actual CD34(-) cells is difficult to distinguish from that due to CD34(+) cells potentially contaminating the preparations...
- Human AML cells in NOD/SCID mice: engraftment potential and gene expression
R Lumkul
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Leukemia 16:1818-26. 2002
....
- Comparisons of alloreactive potential of clinical hematopoietic grafts
W Leung
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 5001, USA
Transplantation 68:628-35. 1999
..We sought to compare the immunoreactive potential of human cord blood (CB) versus normal adult bone marrow (BM) versus mobilized blood (peripheral blood stem cells; PBSC) from cancer patients...
- Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor
K F Tse
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD, USA
Leukemia 15:1001-10. 2001
..The activity against FLT3 suggests a potential therapeutic application for AG1296 or similar drugs in the treatment of leukemias involving deregulated FLT3 tyrosine kinase activity and as a tool for studying the biology of FLT3...
- Characterization of the tyrosine kinase Tnk1 and its binding with phospholipase C-gamma1
D M Felschow
Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, Maryland 21231, USA
Biochem Biophys Res Commun 273:294-301. 2000
..Conversely, GST-Tnk1(PR) protein constructs complexed with endogenously expressed PLC-gamma1. The association of Tnk1 with PLC-gamma1 suggests a role for Tnk1 in phospholipid signal transduction...
High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemiasS Morisot
Department of Pediatrics, Center for Stem Cell Biology and Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Leukemia 24:1859-66. 2010
..This very high frequency of LSCs suggests that a hierarchical LSC model is not valuable for poor-outcome ALL...
- Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production
L D Lewis
Department of Medicine and Pharmacology and Molecular Sciences Division of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Hum Exp Toxicol 23:173-85. 2004
..These findings support the hypothesis that mtDNA is one of the intracellular targets involved in the pathogenesis of AZT-associated bone marrow progenitor cell toxicity...
- Mice deficient in MIM expression are predisposed to lymphomagenesis
D Yu
Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Oncogene 31:3561-8. 2012
....
- Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia
D M Loeb
Division of Pediatric Oncology, Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
Med Pediatr Oncol 37:365-71. 2001
..Ten had grade 3 or 4 GI toxicity. One patient died of sepsis. CONCLUSIONS: HDAC administered as a part of timed sequential therapy yields an excellent remission induction rate with manageable toxicity...
- Identification of a region on the outer surface of the CBFbeta-SMMHC myeloid oncoprotein assembly competence domain critical for multimerization
L Zhang
Divisions of Pediatric Oncology and Immunology and Hematopoiesis, Johns Hopkins University, Baltimore, MD 21231, USA
Oncogene 25:7289-96. 2006
..Each helix mutant retained the ability to bind the mSin3A corepressor. Agents interacting with the outer surface of the CBFbeta-SMMHC ACD that prevent multimerization may be effective as novel therapeutics in AML...
- Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin
C L Schwartz
Division of Pediatric Oncology, Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Baltimore
J Clin Oncol 5:1900-11. 1987
..These results provide the basis for a clinical trial of bone marrow transplantation using combined pharmacologic/immunologic purging of T lymphoblasts from patients' harvested autologous marrow...
- Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38- stem/progenitor cells
G T Hoehn
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 5001, USA
Oncogene 12:903-13. 1996
..1), near the p53 locus. Thus, Tnk1 is a novel tyrosine kinase that may be involved in signalling pathways utilized broadly during fetal development, more selectively in adult tissues and in cell of the lymphohematopoietic system...
